Roivant Sciences Ltd. (NASDAQ:ROIV) Shares Bought by ORG Wealth Partners LLC

ORG Wealth Partners LLC increased its position in shares of Roivant Sciences Ltd. (NASDAQ:ROIV) by 85.7% during the 4th quarter, Holdings Channel.com reports. The fund owned 18,240 shares of the company’s stock after acquiring an additional 8,417 shares during the period. ORG Wealth Partners LLC’s holdings in Roivant Sciences were worth $216,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the company. Gladius Capital Management LP purchased a new stake in Roivant Sciences during the 3rd quarter worth about $35,000. Point72 Hong Kong Ltd purchased a new stake in shares of Roivant Sciences in the 2nd quarter valued at approximately $36,000. US Bancorp DE raised its stake in Roivant Sciences by 146.5% in the third quarter. US Bancorp DE now owns 3,278 shares of the company’s stock valued at $38,000 after buying an additional 1,948 shares in the last quarter. GAMMA Investing LLC raised its stake in Roivant Sciences by 57.0% in the fourth quarter. GAMMA Investing LLC now owns 3,548 shares of the company’s stock valued at $42,000 after buying an additional 1,288 shares in the last quarter. Finally, Quarry LP purchased a new stake in Roivant Sciences during the 2nd quarter worth about $53,000. 64.76% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

ROIV has been the topic of several research analyst reports. HC Wainwright reissued a “buy” rating and set a $18.00 target price on shares of Roivant Sciences in a research report on Wednesday, November 13th. Cantor Fitzgerald reissued an “overweight” rating on shares of Roivant Sciences in a report on Thursday, September 19th. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $17.93.

Roivant Sciences Stock Down 2.6 %

NASDAQ:ROIV traded down $0.29 during trading hours on Friday, reaching $10.73. 2,405,537 shares of the company’s stock were exchanged, compared to its average volume of 4,142,402. The firm has a market capitalization of $7.81 billion, a price-to-earnings ratio of 1.90 and a beta of 1.27. Roivant Sciences Ltd. has a 1-year low of $9.69 and a 1-year high of $13.06. The company has a 50-day moving average of $11.88 and a 200 day moving average of $11.58.

Insider Buying and Selling

In other news, COO Eric Venker sold 177,704 shares of the business’s stock in a transaction that occurred on Monday, December 30th. The stock was sold at an average price of $11.54, for a total value of $2,050,704.16. Following the transaction, the chief operating officer now owns 740,976 shares of the company’s stock, valued at approximately $8,550,863.04. The trade was a 19.34 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CIO Mayukh Sukhatme sold 185,946 shares of the business’s stock in a transaction on Tuesday, December 24th. The shares were sold at an average price of $12.00, for a total transaction of $2,231,352.00. Following the completion of the transaction, the executive now directly owns 18,836,547 shares in the company, valued at $226,038,564. This represents a 0.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 1,942,629 shares of company stock valued at $23,071,486 over the last quarter. 7.90% of the stock is currently owned by insiders.

Roivant Sciences Company Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.